A retrospective study from a U.S. medical center found that patients undergoing transcatheter aortic valve replacement (TAVR) who were treated with novel oral anticoagulants (NOACs) experienced significantly higher mortality and cardiovascular event rates compared to those on antiplatelet therapy alone. Among 171 patients observed, 33% of those on NOACs died within 30 days compared to 12% in the antiplatelet group. The research highlights the concerns over NOAC safety post-TAVR and advocates for further studies on antithrombotic strategies.

Source: Journal of Clinical Medicine